• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Telavancin - Key patent, SPC, and data exclusivity expiry (7 country coverage) Product Image

Telavancin - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • ID: 1532531
  • November 2014
  • Genericsweb Pty Ltd – Ark Patent Intelligence

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Telavancin
Telavancin indications: Treatment of complicated skin and skin structure infections caused by Gram-positive microorganisms; Treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
Telavancin innovator: Theravance (Vibativ, Arbelic); Astellas (Vibativ)

Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display READ MORE >

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos